Alleviation Of Metabolic Endotoxemia In Adults With Metabolic Syndrome With Milk Fat Globule Membrane

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

December 20, 2020

Study Completion Date

December 20, 2020

Conditions
Metabolic SyndromeMetabolic Endotoxemia
Interventions
DIETARY_SUPPLEMENT

MFGM-enriched full-fat dairy milk

MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content). This delivers MFGM at \~10-times that in full-fat dairy milk, which reflects that consumers obtain MFGM from dairy foods other than whole milk.

DIETARY_SUPPLEMENT

Soy phospholipid/lecithin milk

MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content).

Trial Locations (1)

43201

The Ohio State University, Columbus

All Listed Sponsors
lead

Ohio State University

OTHER

NCT03860584 - Alleviation Of Metabolic Endotoxemia In Adults With Metabolic Syndrome With Milk Fat Globule Membrane | Biotech Hunter | Biotech Hunter